These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Update on the clinical assessment and management of thyroid eye disease. Roos JCP; Murthy R Curr Opin Ophthalmol; 2019 Sep; 30(5):401-406. PubMed ID: 31313753 [TBL] [Abstract][Full Text] [Related]
47. Thyroid eye disease: therapy in the active phase. Bhatti MT; Dutton JJ J Neuroophthalmol; 2014 Jun; 34(2):186-97. PubMed ID: 24821102 [TBL] [Abstract][Full Text] [Related]
48. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy? Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069 [TBL] [Abstract][Full Text] [Related]
49. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials. Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425 [TBL] [Abstract][Full Text] [Related]
50. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Moledina M; Damato EM; Lee V Eye (Lond); 2024 Jun; 38(8):1425-1437. PubMed ID: 38374366 [TBL] [Abstract][Full Text] [Related]
51. Thyroid eye disease: current and potential medical management. Pouso-Diz JM; Abalo-Lojo JM; Gonzalez F Int Ophthalmol; 2020 Apr; 40(4):1035-1048. PubMed ID: 31919775 [TBL] [Abstract][Full Text] [Related]
52. Treatment modalities of thyroid related orbitopathy. Ahn ES; Subramanian PS Indian J Ophthalmol; 2014 Oct; 62(10):999-1002. PubMed ID: 25449934 [TBL] [Abstract][Full Text] [Related]
53. A New Era in the Treatment of Thyroid Eye Disease. Patel A; Yang H; Douglas RS Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284 [TBL] [Abstract][Full Text] [Related]
54. Thyroid eye disease: From pathogenesis to targeted therapies. Yoon JS; Kikkawa DO Taiwan J Ophthalmol; 2022; 12(1):3-11. PubMed ID: 35399971 [TBL] [Abstract][Full Text] [Related]
55. Thyroid eye disease: what is new to know? Li Z; Cestari DM; Fortin E Curr Opin Ophthalmol; 2018 Nov; 29(6):528-534. PubMed ID: 30124533 [TBL] [Abstract][Full Text] [Related]
56. Cigarette smoking and thyroid eye disease: a systematic review. Thornton J; Kelly SP; Harrison RA; Edwards R Eye (Lond); 2007 Sep; 21(9):1135-45. PubMed ID: 16980921 [TBL] [Abstract][Full Text] [Related]
57. Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration. Quinn AS; Dujardin LR; Knight B; Benzimra J; Quinn AG; Vaidya B Int Ophthalmol; 2018 Feb; 38(1):301-306. PubMed ID: 28181061 [TBL] [Abstract][Full Text] [Related]
58. Potential utility of rituximab for Graves' orbitopathy. Salvi M; Vannucchi G; Beck-Peccoz P J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. Teo HM; Smith TJ; Joseph SS Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025 [TBL] [Abstract][Full Text] [Related]
60. Hyperthyroid vs hypothyroid eye disease: the same severity and activity. Kashkouli MB; Pakdel F; Kiavash V; Heidari I; Heirati A; Jam S Eye (Lond); 2011 Nov; 25(11):1442-6. PubMed ID: 21818129 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]